TABLE 26.
Important drug–drug interactions between antimalarial agents and antiretroviral therapy drugs.
| Drug | Antimalarial agent | Direction of interaction | Recommendation |
|---|---|---|---|
| InSTI | Coartem (artemether–lumefantrine) | No interaction | Safe to use |
| Atovaquone–proguanil | No interaction | Safe to use | |
| EFV | Coartem | ↓ Artemether and lumefantrine concentrations | Use but might need to repeat the 3-day course of Coartem |
| Atovaquone–proguanil | ↓ Atovaquone and proguanil concentrations | Avoid co-administration | |
| NVP | Coartem | No interaction | Use |
| Atovaquone–proguanil | ↓ Atovaquone concentrations | Avoid co-administration | |
| PI/r | Coartem | ↑ Lumefantrine concentrations | No dose adjustment necessary |
| Atovaquone–proguanil | ↓Atovaquone and proguanil concentrations | Avoid co-administration |
ART, antiretroviral therapy; EFV, efavirenz; InSTI, integrase strand transfer inhibitor; NVP, nevirapine; PI/r, ritonavir-boosted protease inhibitor.